Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the clinical efficacy and economic cost of enucleation after placement of pancreatic duct stents before surgery with that of direct enucleation alone, and to evaluate its safety and feasibility.


Clinical Trial Description

The research contents of this study include: patients with insulinoma near the main pancreatic duct in the head and neck of the pancreas were randomly divided into two groups: the preoperative pancreatic duct stent enucleation group (stended EN), the direct en group (DEN), the Sen group asked a digestive endoscopist to place the pancreatic duct stent before surgery, and the next day or the next day after surgery, and the den group received enucleation directly. The safety of the two groups was compared, including the evaluation of surgical effect Postoperative complications and long-term prognosis based on follow-up data analysis; At the same time, the differences between the two groups were evaluated from the perspective of health economics. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05523778
Study type Interventional
Source Peking Union Medical College Hospital
Contact Qiang Xu, Doctor
Phone +86-13810096103
Email xuqiang@pumch.cn
Status Recruiting
Phase N/A
Start date February 6, 2023
Completion date December 2025

See also
  Status Clinical Trial Phase
Recruiting NCT02021604 - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma Phase 1
Withdrawn NCT02108782 - Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT05034783 - [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients Early Phase 1
Terminated NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Phase 2
Completed NCT00937079 - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Phase 1
Recruiting NCT04185350 - Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma Early Phase 1
Recruiting NCT00001276 - Diagnosing and Treating Low Blood Sugar Levels
Active, not recruiting NCT02121366 - EUS-guided Ethanol Ablation of an Insulinoma N/A
Terminated NCT00084461 - Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00131911 - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00005910 - Laparoscopy to Remove Pancreatic Tumors (Insulinomas) N/A
Recruiting NCT03583528 - DOTATOC PET/CT for Imaging NET Patients
Withdrawn NCT04915144 - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Phase 2
Recruiting NCT02560376 - 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis Phase 0
Completed NCT01525082 - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00655655 - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00075439 - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT04452396 - CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia N/A
Active, not recruiting NCT01824875 - Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1